Make a donation

Monday, October 21 2019

New Drug Reimbursement Recommendation for Pomalyst

The Canadian Agency for Drugs and Technologies in Health recommanded the reimbursement for Pomalidomide (Pomalyst) in combination with dexamethasone and bortezomib for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

See the criteria and condition